尿中双甲度与儿童和青少年肥胖患病率之间的关联
Leonardo Trasande1, Teresa M Attina, Jan Blustein
1Department of Pediatrics, New York University School of Medicine, New York, NY 10016, USA. leonardo.trasande@nyumc.org
JAMA
|September 20, 2012
概括
尿中比斯醇A (BPA) 含量较高与儿童和青少年肥胖患病率增加有关. 这项研究表明,潜在的环境因素有助于儿童肥胖,需要进一步调查BPA暴露和身体质量.
科学领域:
- 环境健康 环境健康
- 儿科内分泌学 儿科内分泌学
- 公共卫生 公共卫生
背景情况:
- 双A (BPA) 是一种在消费品中发现的化学物质,与成年人的健康问题有关.
- 证据将BPA暴露与儿童肥胖症联系在一起是有限的.
- 这项研究调查了BPA与儿童体质之间的关联.
研究的目的:
- 检查尿液BPA度与儿童体质指数 (BMI) 结果之间的关联.
- 为了确定BPA暴露是否是儿童群体肥胖的危险因素.
主要方法:
- 从2003-2008年国家健康和营养检查调查中对2838名儿童和青少年 (年龄在6-19岁) 的横截面分析.
- 测量了尿液中的BPA度,并使用BMI来将参与者分类为超重或肥胖.
- 对各种人口,生活方式和环境因素进行统计分析.
主要成果:
- 尿路BPA最低四分位数的儿童患肥胖的患病率明显低于高四分位数的儿童.
- 对于BMI z分数也观察到类似的模式.
- 这种关联在白人儿童中显著,但在黑人或西班牙裔儿童中没有显著.
结论:
- 尿液中的BPA度与儿童和青少年的肥胖有显著的相关性.
- 这些发现表明BPA可能在儿童肥胖中发挥作用.
- 需要进一步的研究来了解机制,考虑饮食摄入量和脂肪组织储存.
相关概念视频
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Bulimia Nervosa
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...


